Monte Rosa Therapeutics, Inc. GLUE Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s retained earnings?
- Monte Rosa Therapeutics, Inc. (GLUE) reported retained earnings of -$521.72M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s retained earnings changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s retained earnings decreased by 33.2% year-over-year, from -$391.7M to -$521.72M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Monte Rosa Therapeutics, Inc.'s retained earnings has grown at a 58.3% compound annual growth rate (CAGR), from -$48.08M to -$477.21M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.